Compare Biogen Inc (BIIB) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Shell PLC — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Shell PLC trades at $90.53 (market cap $250.44B). The key difference: Shell PLC is far larger — about 8.3× Biogen Inc's market cap, and Shell PLC pays a 3.45% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SHEL | |
|---|---|---|
Market Cap | $30.13B | $250.44B |
Sector | Health | Energy |
52-Week High | $216.63 | $94.15 |
52-Week Low | $128.93 | $70.31 |
Enterprise Value | $37.20B | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
SHEL trades at $90.12, up 0.19% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beating estimates. The stock shows attractive valuation metrics with a P/E of 10.01 and P/S of 0.88, supported by a 14.35% ROE and 8.76% net income margin. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments, such as selling its European renewables unit to TotalEnergies.
Outlook remains positive due to discounted valuation, rising cash flow, and analyst consensus favoring buys with a $103.60 price target. Key risks include commodity price volatility, regulatory pressures, and execution challenges in energy transitions. The stock offers value with upside potential but requires monitoring of oil market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
